Levofloxacin for the treatment of respiratory tract infections

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 8, 2012, Pages 1203-1212

  Torres, Antoni ^a   Liapikou, Adamantia ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b SOTIRIA GENERAL HOSPITAL   (Greece)

Author keywords

Community acquired pneumonia; Hospital pneumonia; Levofloxacin; Quinolones

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME AXETIL; CIPROFLOXACIN; CISPLATIN; CLARITHROMYCIN; ERYTHROMYCIN; GEMIFLOXACIN; IMIPENEM; LEVOFLOXACIN; MOXIFLOXACIN; NONSTEROID ANTIINFLAMMATORY AGENT; OFLOXACIN;

ACUTE EXACERBATION OF CHRONIC BRONCHITIS; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTERIAL SINUSITIS; CHRONIC BRONCHITIS; CLOSTRIDIUM DIFFICILE INFECTION; COMMUNITY ACQUIRED PNEUMONIA; DNA REPLICATION; DNA TRANSCRIPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS PARAINFLUENZAE; HOSPITAL ACQUIRED PNEUMONIA; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; KIDNEY FUNCTION; LENGTH OF STAY; LUNG ALVEOLUS MACROPHAGE; LUNG LAVAGE; MEDLINE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MORAXELLA CATARRHALIS; MORTALITY; MULTICENTER STUDY (TOPIC); MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PATIENT COMPLIANCE; PATIENT SATISFACTION; PHOTOSENSITIVITY; PSEUDOMEMBRANOUS COLITIS; PSEUDOMONAS AERUGINOSA; RECOMMENDED DRUG DOSE; REVIEW; SHORT COURSE THERAPY; SINGLE DRUG DOSE; STEADY STATE; STENOTROPHOMONAS MALTOPHILIA; TREATMENT DURATION; ULTRAVIOLET RADIATION; VENTILATOR ASSOCIATED PNEUMONIA;

ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; HUMANS; OFLOXACIN; RESPIRATORY TRACT INFECTIONS; TREATMENT OUTCOME;

EID: 84861302939     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.688952     Document Type: Review

References (64)

1. Noreddin AM, Elkhatib WF, Cunnion KM, Zhanel GG. Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy. Drug Health Patient Saf 2011;3: 59-68
2. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44 (Suppl 2): S27-72 (Pubitemid 46290553)
3. American thoracic society documents guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated Pneumonia. Am JRespir Crit Care Med 2005;171: 388-416
4. Woodhead M, Blasi F, Ewig S, Joint Taskforce of the European Respiratory Society and European Society for Clinical Microbiology and Infectious Diseases. Guidelines for the management of adult lower respiratory tract infections-full version. Clin Microbiol Infect 2011;17 (Suppl 6): E1-59
5. European Surveillance of Antimicrobial Consumption (ESAC): outpatient quinolone use in Europe (1997 - 2009) Niels Adriaenssens, Samuel Coenen, Ann Versporten, ArnoMuller, Girma Minalu, Christel Faes, Vanessa Vankerckhoven, Marc Aerts, Niel Hens, GeertMolenberghs and Herman Goossenson behalf of the ESAC Project Group
6. Levaquin (levofloxacin tablets, oral solution, injection): US Prescribing Information. Ortho-McNeil Pharmaceutical, Inc.; Raritan (NJ): 2008
7. Anderson VR, Perry CM. Levofloxacin. A review of its use as a high-dose, short-course treatment for bacterial infection. Drugs 2008;68 (4): 535-56
8. Schito GC, Varaldo PE, Nicoletti G. Activity of Levofloxacin on Respiratory Pathogens: Results of the SEMPRE Italian Study (2000 - 2002). ICAAC; Chicago: 2003
9. Noreddin AM, Marras TK, Sanders K, et al. Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500 mg, 750 mg and 1000 mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP). Int J Antimicrob Agents 2004;24 (5): 479-84 (Pubitemid 39425161)
10. Odenholt I, Cars O. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model. J Antimicrob Chemother 2006;58 (5): 960-5
11. Frei CR, Burgess DS. Pharmacodynamic analysis of ceftriaxone, gatifloxacin, and levofloxacin against Streptococcus pneumoniae with the use of Monte Carlo simulation. Pharmacotherapy 2005;25 (9): 1161-7 (Pubitemid 41242575)
12. Drusano GL, Preston SL, Gotfried MH, et al. Levofloxacin penetration into epithelial lining fluid as determined by population pharmacokinetic modeling and Monte Carlo simulation. Antimicrob Agents Chemother 2002;46 (2): 586-9 (Pubitemid 34087223)
13. Capitano B, Mattoes HM, Shore E, et al. Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. Chest 2004;125 (3): 965-97
14. Critchley IA, Jones ME, Heinze PD, et al. In vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae from North America and Europe. Clin Microbiol Infect 2002;8 (4): 214-21
15. Duffy LB, Crabb DM, Bing X, et al. Bactericidal activity of levofloxacin against Mycoplasma pneumoniae [letter]. J Antimicrob Chemother 2003;52 (3): 527-8; 45 (Pubitemid 37120745)
16. Schentag JJ, Meagher AK, Forrest A. Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part 2: human trials. Ann Pharmacother 2003;37 (10): 1478-88 (Pubitemid 37205507)
17. Jones RN. Global epidemiology of antimicrobial resistance among community-acquired and nosocomial pathogens: a five-year summary from the SENTRY antimicrobial surveillance program (1997 - 2001). Semin Respir Crit Care Med 2003;24 (1): 121-34
18. Jones RN, Fritsche TR, Sader HS, et al. Activity of garenoxacin, an investigational des-F (6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values. Diagn Microbiol Infect Dis 2007;58 (1): 9-17 (Pubitemid 46694279)
19. Macia MD, Blanquer D, Togores B, et al. Hypermutation is a key factor in development of multiple- antimicrobial resistance in Pseudomonas aeruginosa strains causing chronic lung infections. Antimicrob Agents Chemother 2005;49: 3382-6 (Pubitemid 41060586)
20. Bonfiglio G. Is levofloxacin as active as ciprofloxacin against pseudomonas aeruginosa? Chemotherapy 2001;47: 239-42 (Pubitemid 32588782)
21. Salkind AR, Cuddy PG, Foxworth JW. Fluoroquinolone treatment of community-acquired pneumonia: a meta-analysis. Ann Pharmacother 2002;36: 1938-43 (Pubitemid 35429568)
22. Fogarty C, Siami G, Kohler R, et al. Multicenter, open-label, randomized study to compare the safety and efficacy of levofloxacin versus ceftriaxone sodium and erythromycin followed by clarithromycin and amoxicillin-clavulanate in the treatment of serious community-acquired pneumonia in adults. Clin Infect Dis 2004;38: S16-23 (Pubitemid 38122237)
23. Anzueto A, Niederman MS, Pearle J, Community-Acquired Pneumonia Recovery in the Elderly Study Group.community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy. Clin Infect Dis 2006;42 (1): 73-81; Erratum in: Clin Infect Dis. 2006 May 1; 42 (9): 1350 (Pubitemid 41832083)
24. Shorr AF, Khashab MM, Xiang JX, et al. Levofloxacin 750-mg for 5 days for the treatment of hospitalized fine risk class III/IV community-acquired pneumonia patients. Respir Med 2006;100 (12): 2129-36 (Pubitemid 44718399)
25. File TM Jr, Milkovich G, Tennenberg AM, et al. Clinical implications of 750 mg, 5-day levofloxacin for the treatment of community-acquired pneumonia. Curr Med Res Opin 2004;20 (9): 1473-81 (Pubitemid 39361352)
26. Peterson J, Khashab MM, Fisher AC, et al. Sustained early resolution of community-acquired pneumonia symptoms following treatment with high-dose, short-course levofloxacin [abstract no. 421 plus poster]. 44th Annual Meeting of the Infectious Diseases Society of America; 12 - 16 October 2006; Toronto
27. Schein J, Janagap-Benson C, Grant R, et al. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the USA: focus on length of stay. Curr Med Res Opin 2008;24 (3): 895-906 (Pubitemid 351429000)
28. Dunbar LM, Khashab MM, Kahn JB, et al. Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens. Curr Med Res Opin 2004;20 (4): 555-63 (Pubitemid 38525164)
29. Carratala J, Fernandez-Sabe N, Ortega L, et al. Outpatient care compared with hospitalization for community-acquired pneumonia: a randomized trial in low-risk patients. Ann Intern Med 2005;142 (3): 165-72 (Pubitemid 40189108)
30. Tillotson GS. Role of gemifloxacin in community-acquired pneumonia. Expert Rev Anti Infect Ther 2008;6 (4): 405-18; Review
31. Alvarez Lerma F, Romero Lujan JL, Moron Jimenez A, Grupo de Estudio de Levofloxacino en UCI. Levofloxacin in the treatment of nosocomial infection in critically ill patients. Rev Esp Quimioter 2008;21 (2): 83-92 (Pubitemid 352018988)
32. Shorr AF, Zadeikis N, Jackson WL, et al. Levofloxacin for treatment of ventilator-associated pneumonia: a subgroup analysis from a randomized trial. CID 2005;40 (Suppl 2): S126-S28
33. Tennenberg AM, Davis NB, Wu SC, et al. Pneumonia due to Pseudomonas aeruginosa: the levofloxacin clinical trials experience. Curr Med Res Opin 2006;22 (5): 843-50 (Pubitemid 43875552)
34. Scheld WM. Maintaining fluoroquinolone class efficacy: review of influencing factors. Emerg Infect Dis 2003;9 (1): 1-9; Review (Pubitemid 36110195)
35. West M, Boulanger BR, Fogarty C, et al. Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized, open- label study. Clin Ther 2003;25 (2): 485-506 (Pubitemid 36286915)
36. Neuhauser MM, Weinstein RA, Rydman R, et al. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 2003;289 (7): 885-8 (Pubitemid 37430348)
37. Canton R, Lodeb H, Graninger W, Milkovich G. Respiratory tract infections: at-risk patients, who are they? Implications for their management with levofloxacin. Int J Antimicrob Agents 2006;28S: S115-27 (Pubitemid 44291535)
38. Shah PM, Maesen FP, Dolmann A, et al. Levofloxacin versus cefuroxime axetil in the treatment of acute exacerbations of chronic bronchitis: results of arandomized, double-blind study. J Antimicrob Chemother 1999;43: 529-39 (Pubitemid 29182303)
39. Masterton RG, Burley CJ. Randomized, double-blind study comparing 5- and 7-day regimens of oral levofloxacin in patients with acute exacerbations of chronic bronchitis. Int JAntimicrob Agents 2001;18: 503-12 (Pubitemid 33152742)
40. Weiss LR. Open-label, randomized comparison of the efficacy and tolerability of clarithromycin, levofloxacin, and cefuroxime axetil in the treatment of adults with acute bacterial exacerbations of chronic bronchitis. Clin Ther 2002;24: 1414-25 (Pubitemid 35176973)
41. Urueta-Robledo J, Ariza H, Jardim JR, MOX-CB Study Group. Moxifloxacin versus levofloxacin against acute exacerbations of chronic bronchitis: the Latin American Cohort. Respir Med 2006;100 (9): 1504-11 (Pubitemid 44089371)
42. Martinez FJ. Acute exacerbation of chronic bronchitis: expanding short-course therapy. Int JAntimicrob Agents 2005;26 (Suppl 3): S156-63; Review
43. Noreddin AM, Hoban DJ, Zhanel GG.comparison of gatifloxacin and levofloxacin administered at various dosing regimens to hospitalized patients with community-acquired pneumonia: pharmacodynamic target attainment study using North American surveillance data for Streptococcus pneumoniae. Int JAntimicrob Agents 2005;26 (2): 120-5 (Pubitemid 41021963)
44. Ho PL, Tse WS, Tsang KWT, et al. Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study. Clin Infect Dis 2001;32: 701-7 (Pubitemid 32221927)
45. Biedenbach DJ, Toleman MA, Walsh TR, Jones RN. Characterization of fluoroquinolone-resistant betahemolytic Streptococcus spp. isolated in North America and Europe including the first report of fluoroquinolone- resistant Streptococcus dysgalactiae subspecies equisimilis: report from the SENTRY Antimicrobial Surveillance Program (1997 - 2004). Diagn Microbiol Infect Dis 2006;55 (2): 119-27 (Pubitemid 43792405)
46. Brown SD, Rybak MJ. Antimicrobial susceptibility of Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus influenzae collected from patients across the USA, in 2001 - 2002, as part of the PROTEKT US study. J Antimicrob Chemother 2004;54 (Suppl 1): i7-1
47. Karlowsky JA, Thornsberry C, Jones ME, et al. Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST Surveillance Program (1998 - 2002). Clin Infect Dis 2003;36 (8): 963-70 (Pubitemid 36513279)
48. Thornsberry C, Sahm DF, Kelly LJ, et al. Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999 - 2000. Clin Infect Dis 2002;34 (Suppl 1): S4-16
49. Canton R, Morosini M, Enright MC, Morrissey I. Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme. J Antimicrob Chemother 2003;52 (6): 944-52 (Pubitemid 38008414)
50. de la Campa AG, Ardanuy C, Balsalobre L, et al. Changes in fluoroquinolone- resistant Streptococcus pneumoniae after 7-valent conjugate vaccination, Spain. Emerg Infect Dis 2009;15: 905-11
51. Ubukata K. Mechanisms of beta-lactam and quinolone resistance in Haemophilus influenzae. Nihon Rinsho 2012;70 (2): 247-50
52. ATS/CDC/IDSA Statement: treatment of tuberculosis (2003). Am J Respir Crit Care Med 2003;167: 603-62
53. Devasia RA, Blackman A, Gebretsadik T, et al. Fluoroquinolone resistance in mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure. Am J Respir Crit Care Med 2009;180 (4): 365-70
54. Torres A, Ewig S, Lode H, Carlet J; For The European HAP working group. Defining, treating and preventing hospital acquired pneumonia: European perspective. Intensive Care Med 2009;35: 9-29
55. Davidson R, Cavalcanti R, Brunton JL, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002;346: 747-50 (Pubitemid 34983995)
56. Rodvold KA, Danziger LH, Gotfried MH. Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults. Antimicrob Agents Chemother 2003;47 (8): 2450-7 (Pubitemid 36919444)
57. Gotfried MH, Danziger LH, Rodvold KA. Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. Chest 2001;119 (4): 1114-22 (Pubitemid 32679439)
58. D'Ignazio J, Camere MA, Lewis DE, et al. Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired pneumonia in adults. Antimicrob Agents Chemother 2005;49: 4035-41 (Pubitemid 41400943)
59. Gotfried MH, Dattani D, Riffer E, et al. A controlled, double-blind, multicenter study comparing clarithromycin extended-release tablets and levofloxacin tablets in the treatment of community-acquired pneumonia. Clin Ther 2002;24: 736-51 (Pubitemid 34596943)
60. File TM Jr, Segreti J, Dunbar L, et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 1997;41 (9): 1965-72 (Pubitemid 27383238)
61. Lin TY, Lin SM, Chen HC, et al. An open label randomized comparison of levofloxacin and amoxicillin/clavulanate plus clarithromycin for the treatment of hospitalized patients with community-acquired pneumonia. Chang Gung Med J 2007;30: 321-32
62. Leroy O, Saux P, Bedos JP, Caulin E.comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors. Chest 2005;128 (1): 172-83 (Pubitemid 40994470)
63. Frank E, Liu J, Kinasewitz G, et al. A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia. Clin Ther 2002;24: 1292-308 (Pubitemid 35026153)
64. Zervos M, Mandell LA, Vrooman PS, et al.comparative efficacies and tolerabilities of intravenous azithromycin plus ceftriaxone and intravenous levofloxacin with step-down oral therapy for hospitalized patients with moderate to severe community- acquired pneumonia. Treat Respir Med 2004;3: 329-36 (Pubitemid 40045497)